Identification and Management of CKD-Associated Pruritus: Current Insights

Overview

Journal Int J Nephrol Renovasc Dis

Publisher Dove Medical Press

Specialty Nephrology

Date 2025 Jan 3

PMID 39748827

Authors

Tomasz Skrzypczak

Anna Skrzypczak

Piotr Nockowski

Jacek C Szepietowski

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease-associated pruritus (CKD-aP) is a frequent and distressing problem for individuals with chronic kidney disease (CKD) and end-stage renal disease. It affects around 20% of those with CKD and 40% of those with end-stage renal disease. Despite its clear association with poorer psychosocial and medical outcomes, it is often underreported by patients and frequently remains unnoticed by healthcare providers. This is likely due to uncertainty regarding its diagnosis and treatment. Most commonly, CKD-aP could be screened with questionnaires like the KDQoL-36 and WI-NRS, chosen for their simplicity and ease of use. Prior treatment studies of CKD-aP were mostly limited by noncontrolled design and small sample size. First CKD-aP medication - difelikefalin a powerful, new therapeutic option was approved by Federal Drug Administration (FDA) in 2021 and European Medicines Agency (EMA) in 2022. Recent expert opinions, clinical trials and metanalysis identified difelikefalin and gabapentinoids as medications of choice in treatment of CKD-aP. All these findings improved current understanding and management of this condition.

References

Carmichael A, McHugh M, Martin A, Farrow M . Serological markers of renal itch in patients receiving long term haemodialysis. Br Med J (Clin Res Ed). 1988; 296(6636):1575. PMC: 2545958. DOI: 10.1136/bmj.296.6636.1575. View

Agarwal R, Burton J, Gallieni M, Kalantar-Zadeh K, Mayer G, Pollock C . Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus. Clin Kidney J. 2023; 16(1):30-40. PMC: 9871858. DOI: 10.1093/ckj/sfac187. View

ODonohue J, Pereira S, Ashdown A, Haigh C, Wilkinson J, Williams R . A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005; 21(8):1041-5. DOI: 10.1111/j.1365-2036.2005.02430.x. View

Zhao X, Sun H, Li W . Efficacy and safety of different systemic drugs in the treatment of uremic pruritus among hemodialysis patients: a network meta-analysis based on randomized clinical trials. Front Med (Lausanne). 2024; 11:1334944. PMC: 11026555. DOI: 10.3389/fmed.2024.1334944. View

Mapar M, Pazyar N, Siahpoosh A, Latifi S, Beladi Mousavi S, Khazanee A . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. G Ital Dermatol Venereol. 2014; 150(4):351-5. View

Nasrollahi A, Miladipour A, Ghanei E, Yavari P, Haghverdi F . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iran J Kidney Dis. 2009; 1(2):73-7. View

Pauli-Magnus C, Klumpp S, Alscher D, Kuhlmann U, Mettang T . Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int. 2001; 20(6):802-3. View

Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M . Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996; 348(9041):1552-4. DOI: 10.1016/s0140-6736(96)04176-1. View

Kuypers D, Claes K, Evenepoel P, Maes B, Vanrenterghem Y . A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant. 2004; 19(7):1895-901. DOI: 10.1093/ndt/gfh202. View

10.

Zucker I, Yosipovitch G, David M, Gafter U, Boner G . Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol. 2003; 49(5):842-6. DOI: 10.1016/s0190-9622(03)02478-2. View

11.

Duque M, Yosipovitch G, Fleischer Jr A, Willard J, Freedman B . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol. 2005; 52(3 Pt 1):519-21. DOI: 10.1016/j.jaad.2004.08.050. View

12.

Inui S . Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015; 8:249-55. PMC: 4433050. DOI: 10.2147/CCID.S55942. View

13.

Kato A, Takita T, Furuhashi M, Takahashi T, Watanabe T, Maruyama Y . Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha. Artif Organs. 2001; 25(6):441-7. DOI: 10.1046/j.1525-1594.2001.025006441.x. View

14.

Murphy M, Reaich D, Pai P, Finn P, Carmichael A . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol. 2003; 148(2):314-7. DOI: 10.1046/j.1365-2133.2003.05172.x. View

15.

Verduzco H, Shirazian S . CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep. 2020; 5(9):1387-1402. PMC: 7486142. DOI: 10.1016/j.ekir.2020.04.027. View

16.

Rigatto C, Collister D, Granger-Vallee A, Girard L, Hingwala J, Karaboyas A . Pathways for Diagnosing and Treating CKD-Associated Pruritus: A Narrative Review. Can J Kidney Health Dis. 2024; 11:20543581241238808. PMC: 11047256. DOI: 10.1177/20543581241238808. View

17.

Szepietowski J, Morita A, Tsuji T . Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses. 2002; 58(2):167-70. DOI: 10.1054/mehy.2001.1505. View

18.

Phan N, Blome C, Fritz F, Gerss J, Reich A, Ebata T . Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2011; 92(5):502-7. DOI: 10.2340/00015555-1246. View

19.

Papa C . Winter itch, dry skin. J Med Soc N J. 1980; 77(12):817-9. View

20.

Weiner D, Vervloet M, Walpen S, Schaufler T, Munera C, Menzaghi F . Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study. Kidney Med. 2022; 4(10):100542. PMC: 9516453. DOI: 10.1016/j.xkme.2022.100542. View